Jove
Visualize
联系我们

相关概念视频

Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

742
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
742
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

457
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
457
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

69
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
69
Signs of Puberty01:27

Signs of Puberty

419
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
419
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

205
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
205
Menopause01:28

Menopause

200
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
200

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

I See the End.

Military medicine·2016
Same author

Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo.

ACS medicinal chemistry letters·2016
Same author

Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2.

Journal of medicinal chemistry·2015
查看所有相关文章
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jul 18, 2025

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

788

激素疗法:丸激素替代疗法

Lindsay Snow1

  • 1Department of Family and Community Medicine - University of North Dakota School of Medicine and Health Sciences, 1301 N Columbia Rd Stop 9037, Grand Forks ND 58202-9037.

FP essentials
|August 21, 2023
PubMed
概括
此摘要是机器生成的。

患有低丸激素水平和症状特征的男性,可能受益于丸激素替代疗法 (TRT). 个性化管理和监测至关重要,可使用非激素选择.

更多相关视频

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.2K
Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
11:51

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making

Published on: March 2, 2011

15.2K

相关实验视频

Last Updated: Jul 18, 2025

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

788
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.2K
Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
11:51

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making

Published on: March 2, 2011

15.2K

科学领域:

  • 内分泌学 在内分泌学.
  • 男人的健康 男人的健康

背景情况:

  • 的水平自然会随着年龄的增长而下降.
  • 当丸不能产生足够的丸激素时,就会发生低雄性.
  • 低丸激素通常被定义为<300-350 ng/dL在两个早上的样本上.

研究的目的:

  • 审查低阴性恋的标准和治疗方法.
  • 讨论替代疗法 (TRT) 的选择和考虑.
  • 为了突出其他非激素药物疗法.

主要方法:

  • 审查当前的指导方针和文献,关于低子腺症和TRT.
  • 讨论诊断标准,包括血清丸激素水平和症状.
  • 探索各种TRT配方及其相关因素.

主要成果:

  • TRT需要确认的阴道腺乱症 (低丸激素+症状).
  • 管理是个性化的,强调了关于风险,利益和期望的共享决策.
  • 可用的TRT配方包括凝和注射,根据成本和偏好进行选择.
  • 使用TRT存在限制,包括禁忌,副作用和有限的长期安全数据,需要密切监测患者.

结论:

  • 阴性腺症的管理需要对患者进行仔细的评估和个性化治疗计划.
  • 替代疗法提供了好处,但由于潜在的风险和有限的长期数据,需要监测.
  • 非激素药物疗法作为特定患者群体的替代品.